Citizens Maintains Market Outperform on Allogene Therapeutics, Raises Price Target to $8

Citizens analyst Reni J. Benjamin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and raises the price target from $5 to $8.